Germany Onychomycosis Market Size, Share, and COVID-19 Impact Analysis, By Type (Distal Subungual, White Superficial, and Proximal Subungual Onychomycosis), By Treatment (Drug Treatment, Oral and Topical), and Germany Onychomycosis Market Insights Forecasts 2023 - 2033

Germany Onychomycosis Market Insights Forecasts to 2033

• The Germany Onychomycosis Market Size was estimated at USD 225.6 Million in 2023 
• The Market Size is Growing at 3.89% CAGR from 2023 to 2033.
• The Germany Onychomycosis Market Size is Expected to Reach USD 330.5 Million by 2033.

The Germany Onychomycosis Market Size is expected to Reach USD 330.5 Million by 2033, Growing at a 3.89% CAGR from 2023 to 2033. 

Market Overview

The market for products or services used in identifying and treating onychomycosis, a fungal infection of the nails, is known as the onychomycosis market. A bacterial illness called onychomycosis affects the nails, changing their respective positions, texture, and appearance. Although toenails are more frequently infected, both fingernails and toenails can be affected. Among the fungi that cause the infection are molds, yeasts, and dermatophytes. Initially utilized to refer to a non-dermatophytic nail infection, onychomycosis is now used to refer to any fungal nail infection.  The disease is identified by white to yellow-brown nail discoloration, ragged, crumbly nail texture, and distortion of nail shape.  It is generally addressed with laser therapy and photodynamic therapies.  It is usually detected by culture, histological assessments of nail clippings and biopsies, oxygen, potassium, and hydrogen analysis. The increasing incidence of onychomycosis, increased knowledge of its treatment, more studies and development for the creation of new medications, and an increasing percentage of elderly and diabetic people are all contributing to the market's expansion. The main variables driving the market's expansion are rising rates of chronic illness and onychomycosis, as well as increased efforts to research and develop for the discovery of new drugs.  

Report Coverage

This research report categorizes the market for Germany onychomycosis market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Germany onychomycosis market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Germany onychomycosis market.

Driving Factors

The market is driven by the onychomycosis's growing prevalence is one of the key drivers driving the market's growth. Toenail onychomycosis infection is much more prevalent than fingernail onychomycosis infection. The market is expected to be driven by the growing incidence of dermatophyte-induced nail fungal infections and a considerable increase in prescriptions. Since the onychomycosis infections are so prevalent, it is generally accepted that treatments are necessary. R&D is usually handled by small, research-based pharmaceutical and biotechnology firms, whereas larger firms usually concentrate on more profitable products. Additionally, larger companies are using acquisition strategies to diversify their antifungal drug portfolio.

Restraining Factors

The market for onychomycosis faces a number of barriers, such as low patient adherence to treatment plans, a lack of understanding regarding the condition and its management, and the difficulty of treating the infection because it is firmly embedded in the nail plate. Significant obstacles are also presented by the high prevalence of recurrence and the scarcity of safe and effective treatment options, particularly with severe cases.

Market Segment

• The distal subungual segment held the highest share in 2023 and is estimated to grow at a significant CAGR during the forecast period. 

Based on the type, the Germany onychomycosis market is divided into distal subungual, white superficial, and proximal subungual onychomycosis. Among these, the distal subungual segment held the highest share in 2023 and is estimated to grow at a significant CAGR during the forecast period.  The huge market share is due to the growing incidence and number of generic FDA approvals to cater to the growing demands. Moreover, a growing number of pipeline products are being developed to cater to the increasing demands of active pharmaceuticals.

• The drug treatment segment accounted for the largest share in 2023 and is anticipated to grow at a significant CAGR during the projected timeframe.

Based on treatment, the Germany onychomycosis market is divided into drug treatment, oral and topical. Among these, the drug treatment segment accounted for the largest share in 2023 and is anticipated to grow at a significant CAGR during the projected timeframe. Terbinafine, ciclopirox, Jublia, Fluconazole, Penlac, ciclodan, ketoconazole, Sporanox, Itraconazole, Kerydin, efinaconazole, griseofulvin, and others are some of the drugs used to treat onychomycosis. Drugs remain the first-line therapy for the treatment of onychomycosis and have a strong market presence due to an ever-increasing success rate. 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Germany onychomycosis market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Bausch Health Companies Inc.
• Teva Pharmaceutical Industries Ltd.
• Abbott
• Pfizer Inc.
• Merck & Co., Inc.
• Sun Pharmaceutical Industries Ltd.
• Cipla Inc.
• GSK plc
• Others

Key Target Audience

•   Market Players
•   Investors
•   End-users
•   Government Authorities 
•   Consulting and Research Firm
•   Venture capitalists
•   Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the regional and country levels from 2023 to 2033. Spherical Insights has segmented the Germany onychomycosis market based on the below-mentioned segments:

Germany Onychomycosis Market, By Type  

• Distal Subungual
• White Superficial
• Proximal Subungual Onychomycosis

Germany Onychomycosis Market, By Treatment 

• Drug Treatment
• Oral
• Topical